Alveo Technologies and Corteva Agriscience Collaborate to Advance Molecular Crop Disease Diagnostics and Improve Crop Yields

Companies aim to develop point-of-need diagnostics to help protect farmers' fields

ALAMEDA, Calif., Oct. 24, 2023 /PRNewswire/ -- Alveo Technologies, Inc. today announced a collaboration with Corteva Agriscience to expand the offering of its novel eco-friendly molecular sensing and disease diagnostics technology to include a first-in-field agricultural disease diagnostic.

Alveo Technologies and Corteva Agriscience collaborate to advance molecular crop disease diagnostics

Alveo has developed a rapid, handheld, portable medical-grade platform that pairs advanced molecular assays with cloud-enabled data analytics for real-time disease, pathogen analysis, and diagnosis. Using this highly sensitive multiplexed molecular testing platform, Corteva scientists aim to design crop-specific assays to detect pathogens in the field.

"Alveo has developed a game changing, mobile 'molecular lab' that can deliver highly sensitive and specific diagnostic testing where it is needed, which can help solve some of the world's most complex problems, like pandemics and global food crises," said Alveo CEO Shaun Holt. "Our collaboration with Corteva reflects our core focus of taking molecular testing out of the lab and directly to the point of need where it can deliver insight and guidance. This partnership extends the technology beyond healthcare and into agricultural applications."

"Corteva Agriscience explores the latest technologies as we strive to bring actionable insights and solutions to farmers where and when they need them," said Gina Zastrow-Hayes, Technical Director, Seed, R&D & Biotechnology, Corteva. "We are pleased to explore this feasibility with Alveo and are excited by the potential that in-field molecular testing platforms hold for the agricultural industry."

Alveo's be.well™ platform is a point-of-care infectious disease diagnostic platform that utilizes the company's proprietary and globally patented method for the direct electrical sensing of nucleic acid amplification. This technology eliminates the need for specialized lighting and expensive optical detectors, while also simplifying certain aspects of primer manufacturing, providing a more robust and reliable diagnostic instrument. Corteva scientists will explore three components of the platform to develop agri-based assays: the be.well™ Analyzer, a portable, palm-sized, rechargeable device; the be.well™ Cartridge which contains the reagents required for an isothermal amplification reaction; and the be.well Mobile App which offers step by step guidance on administering the test, cloud-connectivity for reporting and tracking results, and back-end analytics for deeper insights into pathogen behavior.

This collaboration reflects both companies' open-source philosophy and desire to build together across sectors and technologies.

About Alveo
At Alveo, we strive to improve outcomes by making molecular detection and diagnostics universally accessible – whether that means on the farm, in the clinic, or even within industrial processes. We understand the value of detecting pathogens earlier where decisions and results can be most effective and impactful. Alveo's be.well™ platform technology encompasses a unique method of nucleic acid amplification coupled with our proprietary direct electrical sensors, enabling improved outcomes across numerous market sectors and verticals at the point of need. Our platform was designed from the bottom up to enable detection and diagnosis of pathogens earlier given its portability, ease of use, robust and rugged design, multiplexing capability, high accuracy, coupled with fast times to result. Cloud connected and Bluetooth enabled, advanced data and analytics are available for reportable diseases, and monitoring and surveillance of new and emerging pathogens. Our aim is to help customers and patients prevent or significantly limit the negative, destructive impact viruses, fungi, bacteria, and other pathogens can have on our planet. In doing so, we are providing actionable insights at lightspeed, improving health outcomes, saving time, reducing cost, and improving yields. With Alveo, we Know Sooner, Act Faster™.

To learn more, visit

About Corteva
Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at

Follow Corteva on Facebook, Instagram, LinkedIn, Twitter and YouTube.

Cautionary Statement on Forward-looking Statements
This release contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's regulatory approvals, product development, product offerings and expected performance are forward-looking statements. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent reports on Form 10-Q and Current Reports on Form 8-K.

Media Contact:
Jeff Miller
Market Street Group for Alveo Technologies, Inc.

Cision View original content to download multimedia:

SOURCE Alveo Technologies

Company Codes: NYSE:CTVA

Back to news